Inclusion Criteria:  Men and women between the ages of 18 and 65 at the time of dupilumab initiation. Subjects must have either one keloid with ≥ 2 cm length-wise or at least two keloids with ≥ 0.4 cm (width) x 0.4 cm (length) Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed.  Exclusion Criteria:  History of an ongoing, chronic or recurrent infectious disease, or evidence of tuberculosis (Tb) infection as defined by a positive QuantiFERON TB-Gold test at screening. Known infection with HIV, hepatitis B or hepatitis C at screening. Are currently pregnant, breastfeeding, or planning to get pregnant during the study. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 8 weeks after stopping treatment. Methods of acceptable birth control are listed below under "Women of Childbearing Potential" Previous hypersensitivity reaction to dupilumab. Patients with acute asthma, acute bronchospasm or status asthmaticus. Patients with known helminth infections. Currently on any other immunosuppressant systemic medication or within 28 days of baseline visit. Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy. Are participating in another study using an investigational agent or procedure during participation in this study or within 28 days prior to baseline visit. Any other treatment for keloids with 28 days prior to baseline visit, including silicone gel/sheets, laser therapy, intralesional steroid or 5-fluorouracil injections, topical steroid, cryotherapy, surgery, or radiation therapy. Has had a live vaccine